Pa. provider latest to earn EMRAM Stage 7

WellSpan Surgery and Rehabilitation Hospital is the latest healthcare provider to receive the EMRAM Stage 7 award from HIMSS Analytics.

Stage 7 is the highest level of the Electronic Medical Record Adoption Model (EMRAM).

HIMSS Analytics developed the EMR Adoption Model in 2005 as a methodology for evaluating the progress and impact of EMR systems for hospitals in the HIMSS Analytics Logic.

During the third quarter of 2015, only 4.1 percent of the more than 5,400 U.S. hospitals in the HIMSS Analytics Logic received the Stage 7 Award.

“WellSpan Surgery and Rehabilitation Hospital is an exceptional facility that was built around leveraging the electronic medical record, and it is deserving of the recognition it has achieved,” said R. Hal Baker, MD, senior vice president, clinical improvement and chief information officer, WellSpan Health. “We appreciate the reviewers' particular recognition of WellSpan’s exceptional integration of biomedical devices with the electronic medical record.”

WellSpan Health is an integrated health system serving the communities of central Pennsylvania and northern Maryland. The organization is comprised of a multispecialty medical group of more than 850 physicians and advanced practice clinicians, a home care organization, six respected hospitals, more than 15,000 employees and more than 140 patient care locations.

“A couple of themes that clearly stood out during our visit to WellSpan Health included strong operational and governance support of their overall EHR efforts and a commitment to clinical leadership in their IT strategy,” said John H. Daniels, CNM, FACHE, FHIMSS, CPHIMS, global vice president, healthcare advisory services group, HIMSS Analytics. “This approach was evident in the case studies they presented that showed significant benefits realization in improved outcomes and cost savings.”

WellSpan Surgery and Rehabilitation Hospital will be recognized at the 2016 HIMSS Conference & Exhibition in Las Vegas which begins on Feb. 29.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.